栾鑫 研究员

　　   栾鑫  研究员

　　  上海中医药大学研究员、博士生导师

　　  交叉科学研究院中药系统药理学研究中心主任

　　  中药功效成分发掘与利用全国重点实验室PI

      上海市中药化学生物学前沿研究基地副主任

　　  国家优秀青年基金获得者

　　  上海市曙光学者

      上海市东方学者特聘教授

　　  上海市青年科技启明星

　　  中华中医药学会青年托举人才

            基本信息丨招生专业丨教育及任职经历丨个人简介丨科研项目丨代表性文章

2007.9-2011.7    中国药科大学药学院                     学士

2011.9-2016.6    上海交通大学医学院                     博士

2015.9-2016.4    美国密西根大学药学院                 联合培养博士研究生

2016.7-2018.7    美国密西根大学药学院                 博士后研究员 

2018.8-2020.9   上海中医药大学交叉科学研究院    副研究员、硕士生导师

2020.10-至今     上海中医药大学交叉科学研究院    研究员、博士生导师、中心主任

个人简介与研究方向

长期聚焦中药来源抗肿瘤活性成分靶点发现及作用机制研究，建立了基于中药化学生物学和药理学技术的中药活性小分子靶标机制解析、天然活性多肽发现及创新应用等系列关键技术平台，从临床有效抗肿瘤中药出发，成功阐明鸦胆子苦素D、隐丹参酮、川楝素、蜂毒肽、鲎素等10余种中药来源抗肿瘤活性成分的直接靶标及作用机制。

先后主持国家自然科学基金优秀青年基金、面上项目、青年项目、国家重点研发计划子课题等科研项目10余项。以第一/通讯作者（含并列）身份在Trends Cancer，J Am Chem Soc，Adv Sci，Cell Rep Med，Drug Resist Updat，Trends Mol Med，Bioact Mater，Nat Prod Rep，APSB，Chem Eng J，Theranostics，JCI Insight，J Med Chem等期刊发表SCI论文60余篇，IF>10论文27篇，引用4700余次，ESI高被引论文3篇。申请发明专利14项，授权6项，连续四年入选药学领域全球2%顶尖科学家榜单（2022-2025），获批I类新药临床试验批件1项。应邀担任Front Pharmacol, J Ethopharmacol，Chinese Medicine and Culture，Chinese Journal of Natural Medicine，中草药及中国药理学通报等多本期刊的编委；Adv Sci，APSB，Biomaterials，Small，Theranostics，J Med Chem等多本SCI杂志审稿人，参编规划教材4部，主编英文专著1部。兼任中华中医药学会青年委员会委员，中国药理学会肿瘤药理专委会委员、中国药学会中药与天然药物专委会青年委员、上海市药学会药理专委会副主任委员。

代表性文章

1.      Lin J#, Zhang X#, Cheng A#, Ren M, Yao X, Sun X, Liang R, Lu S, Gao L, Kan Y, Wang B, Wu Y*, Chen H*, Zhang W*,Luan X*. Delivery of Peptide-LYTAC via Polyporus Polysaccharide Microneedles for Targeted CD47 Degradation and Enhanced Tumor Immunotherapy. J Am Chem Soc. 2025 Jul 16;147(28):25004-25016. doi: 10.1021/jacs.5c08368. IF:15.6.

2.      Xiong Q#, Jin J#, Lin J, Zhang B, Jiang Y, Sun Z, Zhang L, Wu Y, Zhao G, Qin JJ*, Luan X*. The role of synthetic lethality in overcoming cancer therapy resistance: Emerging paradigm and recent advances. Drug Resist Updat. 2025 Nov;83:101290. doi: 10.1016/j.drup.2025.101290. IF:21.7.

3.      Zhou W#, Jin J#, Chen H*, Zhang W*, Luan X*. Fueling the revolution: RIBOTACs manipulating RNA decay. Trends Cancer. 2025 Sep 13:S2405-8033(25)00209-2. doi: 10.1016/j.trecan.2025.08.011. IF:17.5.

4.      Sun Z#, Wu R#, Liang X, Shi T, Zhang Y, Pan Z, Zhang W*, Luan X*. MLCK inhibition induces synthetic lethality in MYC-driven cancer. Cancer Lett. 2025 Aug 10;625:217803. doi: 10.1016/j.canlet.2025.217803. IF:10.1.

5.      Lin JY#, Wu Y#, Liang XH, Tang M, Sun X, Lu SX, Jin JM, Guo X, Wang B, Chen HZ*, Zhang WD*, Luan X*. A Self-Assembling LYTAC Mediates CTGF Degradation and Remodels Inflammatory Tumor Microenvironment for Triple-Negative Breast Cancer Therapy. Adv Sci. 2025, e2500311. doi: 10.1002/advs.202500311. Online ahead of print. IF:14.1.

6.      Lu S#, Zhang X#, Lin J, Liang R, Gong Y, Gao L, Cheng A, Lu X, Chen H, Wu Y *, Zhang W*, Luan X*. Diselenide bond-stapled β-hairpin peptide-loaded hydrogel system for boosting oncolytic immunotherapy. Chemical Engineering Journal. 2025,505:159076. doi.org/10.1016/j.cej.2024.159076. IF:13.2.

7.      Liu Y#, Sun Q#, Guo J#, Yan L#, Yan Y, Gong Y, Lin J, Yuan H, Jin J, Wang B, Chen H, Zhang L*, Zhang W*, Luan X*. Dual ferroptosis induction in N2-TANs and TNBC cells via FTH1 targeting: A therapeutic strategy for triple-negative breast cancer. Cell Rep Med. 2025,6(1):101915. doi: 10.1016/j.xcrm.2024.101915. IF:10.6.

8.      Ren M#, Sun X#, Lin J, Kan Y, Lu S, Zhang X, Liang R, Wang B, Chen H*, Wu Y*, Luan X*. Hypoxia-responsive oncolytic conjugate triggers type-II immunogenic cell death for enhanced photodynamic immunotherapy. J Control Release. 2025, 382:113717. doi: 10.1016/j.jconrel.2025.113717. Online ahead of print. IF:11.5.

9.      Lu X*, Jin J*, Wu Y*, Lin J, Zhang X, Lu S, Zhang J, Zhang C, Ren M, Chen H*, Zhang W*, Luan X*. Self-assembled PROTACs enable protein degradation to reprogram the tumor microenvironment for synergistically enhanced colorectal cancer immunotherapy. Bioact Mater. 2024,43:255-272. doi: 10.1016/j.bioactmat.2024.09.022. IF:20.3.

10.  Gu WJ#, Liu XX#, Shen YW#, Gong YT, Chen YL, Lin J, Lu D, Zhang LJ, Chen HZ, Jin Y, Zhan ZJ*, Zhang WD*, Jin JM*, Luan X*. TRIM4 enhances small-molecule-induced neddylated-degradation of CORO1A for triple negative breast cancer therapy. Theranostics. 2024,14(18):7023-7041. doi: 10.7150/thno.97662. IF:13.3.

11.  Bian HT#, Liang XH#, Lu D#, Lin JY, Lu XC, Jin JM, Zhang LY, Wu Y*, Chen HZ*, Zhang WD*, Luan X*. In Silico Discovery of Stapled Peptide Inhibitor Targeting the Nur77-PPARγInteraction and Its Anti-breast-cancer Efficacy. Adv Sci, 2024, 11(26):e2308435. doi: 10.1002/advs.2023084355. IF:14.1.

12.  Zhang X#, Wu Y#, Lin J, Lu S, Lu X, Cheng A, Chen H*, Zhang W*, Luan X*. Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges. Acta Pharm Sin B. 2024,14(9):3818-3833. doi: 10.1016/j.apsb.2024.05.013. IF:14.6.

13.  Liang R, Cheng A, Lu S, Zhang X, Ren M, Lin J, Wu Y*, Zhang W*, Luan X*. Seleno-amino Acid Metabolism Reshapes the Tumor Microenvironment: from Cytotoxicity to Immunotherapy. Int J Biol Sci. 2024,20(7):2779-2789. doi: 10.7150/ijbs.95484. IF:10.0.

14.  Lu X#, Jin JM#, Wu Y#, Liu X, Liang X, Lin J, Sun Q, Qin JJ*, Zhang W*, Luan X*. Progress in RAS-targeted therapeutic strategies: From small molecule inhibitors to proteolysis targeting chimeras. Med Res Rev. 2024, 44(2):812-832. IF:11.6.

15.  Gong YT#, Zhang LJ#, Liu YC#, Tang M, Lin JY, Chen XY, Chen YX, Yan Y, Zhang WD*, Jin JM*, Luan X*. Neutrophils as potential therapeutic targets for breast cancer. Pharmacol Res. 2023, 198:106996. IF:10.5.

16.  Lin JY, Liu HJ, Wu Y, Jin JM, Zhou YD, Zhang H, Nagle DG, Chen HZ*, Zhang WD*, Luan X*. Targeted Protein Degradation Technology and Nanomedicine: Powerful Allies against Cancer. Small, 2023, e2207778. IF:12.1.

17.  Lu L#, Zhang H#, Zhou YD, Lin JY, Gao WD, Yang T, Jin JM, Zhang LJ, Nagle DG, Zhang WD, Wu Y*, Chen HZ*, Luan X*. Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer. Theranostics, 2022, 12(7):3456-3473. IF:13.3.

18.  Huang R#, Zhang LJ#, Jin JM#, Zhou YD, Zhang HW, Lv C, Lu D, Wu Y, Zhang H, Liu SH, Chen HZ*, Luan X*, Zhang WD*. Bruceine D inhibits HIF-1a-mediated glucose metabolism in hepatocellular carcinoma by blocking ICAT/b-catenin interaction. Acta Pharm Sin B, 2021, 11(11):3481-3492. IF:14.6.

19.  Lin JY#, Jin JM#, Shen YW#, Zhang LJ, Gong G, Bian HT, Chen HZ, Nagle DG, Wu Y*, Zhang WD*, Luan X*. Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins. Theranostics, 2021, 11(17):8337-8349. IF:13.3.

20.  Luan X#, Yuan H#, Song Y#, Hu H, Wen B, He M, Zhang H, Li Y, Li F, Shu P, Burnett JP, Truchan N, Palmisano M, Pai MP, Zhou S*, Gao W*, Sun D*. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation. Biomaterials, 2021, 275:120910. IF:12.9.

21. Luan X#, Wu Y#, Shen YW, Zhang H, Zhou YD., Chen HZ, Nagle DG*, Zhang WD*. Cytotoxic and antitumor peptides as novel chemotherapeutics. Nat Prod Rep, 2021, 38(1):7-17. IF:10.6，封面论文。

22.  Shen YW, Zhou YD, Chen HZ, Luan X*, Zhang WD*. Targeting CTGF in Cancer: An Emerging Therapeutic Opportunity. Trends Cancer, 2021, 7(6):511-524. IF:17.5.

23.  Shen YW, Zhou YD, Luan X*, Zhang WD*. Blocking CTGF-Mediated Tumor-Stroma Interplay in Pancreatic Cancer. Trends Mol Med, 2020, 26(12):1064-1067. IF:13.8.

24.  Jin JM#, Wu Y#, Chen JJ, Shen YW, Zhang LJ, Zhang H, Chen LL, Yuan HB, Chen HZ, Zhang WD*, Luan X*. The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination. Theranostics, 2020,10(22):10141-10153. IF:13.3，封面论文。

25.  Luan X#, Guan YY#, Liu HJ, Lu Q, Zhao M, Sun D, Lovell JF, Sun P, Chen HZ*, Fang C*. A tumor vascular-targeted interlocking trimodal nanosystem that induces and exploits hypoxia. Adv Sci, 2018, 5(8): 1800034. IF:14.1，封面论文。

26.  Luan X#, Guan YY#, Lovell JF, Zhao M, Lu Q, Liu YR, Liu HJ, Gao YG, Dong X, Yang SC, Zheng L, Sun P, Fang C*, Chen HZ*. Tumor Priming Using Metronomic Chemotherapy with Neovasculature-Targeted, Nanoparticulate Paclitaxel. Biomaterials, 2016, 95: 60-73. IF:12.9.

27.  Guan YY#, Luan X#, Xu JR, Liu YR, Lu Q, Wang C, Liu HJ, Gao YG, Chen HZ*, Fang C*. Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis. Biomaterials, 2014, 35(9):3060-70. IF:12.9.